SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is surging in community discussions as investors rally behind its organic growth model and active engagement, which is currently focused on regaining its ticker and chart status on major financial platforms. Supporters are framing this as a patient, long-term building project that stands in contrast to the volatility and rug-pull risks often associated with similar meme-themed assets.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently the subject of intense retail and institutional debate, driven by a rare public endorsement from President Trump that triggered a volatile liquidity event amidst broader concerns over AI software valuations. Investors are actively split between those who view the pullback as a buying opportunity based on the company's entrenched government contracts, and skeptics who highlight potential sector-wide rotation out of crowded SaaS and AI-linked positions.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a significant multi-year cloud infrastructure deal with Anthropic to support its Claude models, signaling sustained demand for high-performance AI compute. While the partnership has fueled bullish sentiment around its expanding roster of major AI clients, traders are simultaneously debating the impact of the company's concurrent upsized debt offering and broader market volatility.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently the center of intense debate as investors weigh whether the recent sell-off represents a structural reset or a temporary exhaustion event amid fears of AI-driven disruption. While some traders point to deeply oversold technical levels and institutional accumulation as signs of a potential bottom, others argue that valuation compression and the rise of competitive AI models continue to create significant headwinds for traditional SaaS business models.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing aggressive volatility and intense debate, driven by a rapid price surge that has triggered a divide between retail momentum traders and short sellers questioning the company's valuation against its current revenue. The community is actively discussing the stock's parabolic move, the impact of a new capital-raising program, and conflicting perspectives on whether the semiconductor testing equipment maker is an overextended speculative bubble or a long-term play on silicon photonics and AI infrastructure.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing significant investor attention as market participants debate its long-term fundamental value and potential as a core DeFi infrastructure play, fueled by recent governance proposals for token buybacks and strategic roadmap updates. The community remains deeply divided, with many traders highlighting the protocol's institutional utility and undervalued metrics, while others express frustration over price volatility and comparative performance against other DeFi assets.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is facing significant retail skepticism and volatility as investors weigh the company's rebranding to 'HELP' and its transition to a NASDAQ listing against a history of dilution and poor stock performance. The community is actively debating the company's clinical pipelinespecifically Phase 3 MDD and Phase 2 GAD datawhile expressing deep frustration over management's communication, the ticker symbol's irony, and the stock's persistent downward trend.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing a sharp sell-off driven by a UBS downgrade and deepening investor anxiety regarding the potential impact of AI disruption on traditional enterprise software business models. The stock has seen massive volume and heavy put activity as the community debates whether this is a structural repricing of the SaaS sector or a tactical buying opportunity fueled by sentiment exhaustion and extreme oversold conditions.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is currently trending as investors debate whether the recent sharp sell-off is a fundamental breakdown driven by AI-related disruption or a massive overreaction to bearish sentiment. While community sentiment is heavily divided, many are treating the pullback as a long-term opportunity to buy a profitable, high-margin leader at valuation levels not seen in years, pointing to share buyback acceleration and a strong competitive moat as key catalysts for a potential reversal.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing significant downward pressure as market sentiment shifts against high-multiple SaaS stocks, despite the company reporting strong revenue growth and expanded partnerships with major AI players. Investors remain deeply divided, with some betting on a long-term AI-driven recovery while others focus on structural concerns regarding profitability, insider selling, and the broader competitive threat posed by next-generation AI agents.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN

Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE:BHVN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange...

Biohaven (NYSE:BHVN) Trading Down 5.3%  - Here's Why

Biohaven (NYSE:BHVN) Stock Price Down 5.3% - Time to Sell...

Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock

Citigroup boosted their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a "buy" rating in a report on Thursday...

Biohaven (NYSE:BHVN) Shares Up 10.5% - Here's Why

Biohaven (NYSE:BHVN) Stock Price Up 10.5% - Still a Buy...

Biohaven (NYSE:BHVN) Trading 6.2% Higher - Here's Why

Biohaven (NYSE:BHVN) Trading Up 6.2% - What's Next...

JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN

JPMorgan Chase & Co. trimmed its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 48.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,335,455 shares of the company's stock after selling 1...

Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages

Biohaven Ltd. (NYSE:BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have is...

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel...

TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00

TD Cowen upped their price objective on Biohaven from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026.</li><li>CEO Ian Mortimer said that the trial results “exceeded expectations.”</li><li>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout.</li></ul><p><br>Xenon Pharmaceuticals Inc. (XENE) on Monday announced that it has commenced an underwritten public offering of $500 million of its common shares on the heels of the company announcing positive results from a trial of azetukalner in focal onset seizures (FOS).</p><p>The company said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to a placebo.</p><p>Shares of XENE closed 50% higher in the regular hours of trading.</p><h2 class="st-heading-2">Trial Data</h2><p>With the higher 25 mg dose, a 53.2% median percent change from baseline in monthly FOS frequency was observed, compared with 10.4% for the placebo, the company said.</p><p>Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies, prompting the company to plan submitting a new drug application to the U.S. Food and Drug Administration (FDA) for the treatment of focal onset seizures in the third quarter of 2026.</p><p>CEO Ian Mortimer said that the trial results “exceeded expectations.”</p><p>“Epilepsy is one of the most common neurological diseases, and foundational antiseizure medications do not provide sufficient seizure control for up to 50% of patients, so we are very optimistic about the opportunity for azetukalner to meaningfully shift the epilepsy treatment paradigm,” said CMO Chris Kenney.</p><p>Focal onset seizures, or epilepsy, originate in one localized area of the brain, causing symptoms based on that specific region.</p><h2 class="st-heading-2">Wall Street Reaction</h2><p>Following the trial data announcement, several analysts hiked their price targets on the stock, while also reflecting on the news’ impact on the shares of Biohaven (<a href="https://stocktwits.com/symbol/BHVN">BHVN</a>), which is developing an investigational drug Opakalim for epilepsy, depression, and pain.</p><p>Jefferies raised the firm's price target on Xenon Pharmaceuticals to $100 from $65 and kept a ‘Buy’ rating on the shares. The firm said it thinks azetukalner has the attributes of a top-selling epilepsy pill, driven by best-in-class focal epilepsy data. In 2026, Xenon shares could grind higher as Big Pharma interest rises and as the Street gauges azetuklaner's peak sales potential, the analyst told investors in a research note.</p><p>RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $80 from $59 and kept an ‘Outperform’ rating on the shares, citing a belief that today's "strong" azetukalner data further increases the likelihood that the drug will be approved. The firm, which now estimates 90% odds of success, also sees higher market uptake than previously anticipated and greater potential for the drug to be priced at a premium.</p><h2 class="st-heading-2">Biohaven Still Holds Chance</h2><p>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout. Azetukalner showed efficacy in-line with expectations, but with a meaningful safety disadvantage, giving opakalim room to differentiate, it said. The firm believes the results continue to highlight an opportunity for opakalim, or BHV-7000, which has shown meaningful evidence of efficacy with better safety and tolerability.</p><p>Raymond James expects Biohaven to present topline results from the first pivotal trial for opakalim, testing a 25 mg and 50 mg dose, in the second half of 2026, which will more concretely establish the target product profile.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around XENE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/XENE">XENE stock</a> has gained 83% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vrtx-soars-in-extended-hours-after-experimental-drug-shows-positive-changes-in-autoimmune-kidney-disease/cZdVDGuRIed">VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.

Equity

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.


Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Current Price	$9.17
Prev Close	$9.39
Open	$9.39
Dividend Yield	0.00%
50-Day Moving Average	$10.37
Beta	1.60
Avg. Volume	2.59M
PE Ratio	-1.32

52-Week High	$24.06
52-Week Low	$7.48
Market Capitalization	$1.41B
EPS (Annual)	-$6.86
Price to Book	23.38
Revenue Per Employee	$0.00

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd